All News

SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

d Jack Cush, MD

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
Malar,rash,SLE, Lupus

Rising Incidence of Systemic Lupus Erythematosus

d Jack Cush, MD

Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.



SLE was diagnosed using the EULAR/ACR criteria and looked at patients seen between 1976–2018.

Read Article
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

d Jack Cush, MD

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

Read Article
lumbar,spine,lbp,pain

Acute Inflammatory Responses Needed to Resolve Chronic Pain

d Jack Cush, MD

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Read Article
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign? https://t.co/s5duGwoWeo https://t.co/lTqBKBHg0g

Links:

Dr. John Cush RheumNow ( View Tweet)
Multimorbidity Burden in Rheumatoid Arthritis Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA. https://t.co/vgC1dCA7kZ https://t.co/fLOaa1PDGU

Links:

Dr. John Cush RheumNow ( View Tweet)
Rising Incidence of Systemic Lupus Erythematosus Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing. https://t.co/LCDmVS5UVb https://t.co/f3z6BlURkj

Links:

Dr. John Cush RheumNow ( View Tweet)
The global axial spondyloarthritis (therapeutics) market was estimated to be at $1.87 Billion in 2021, and is expected to grow to $7.9 billion by 2032 https://t.co/P9TUUBoneM https://t.co/qfBdkvCdru

Links:

Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: Spondyloarthritis Spectrum https://t.co/4QW8dNGJQq

Links:

Dr. John Cush RheumNow ( View Tweet)

@RheumNowNews has already taken a shot at this but let us try : HOW MANY RITUXIMAB pts do you have on EVUSHELD pre exposure prophylaxis for #COVID19 @CCalabreseDO @PaulSaxMD @philipcrobinson @JYazdanyMD @DrPujaMehta1 @jeffsparks @zach_wallace_md @alhkim

Leonard Calabrese LCalabreseDO ( View Tweet)

And now the paper that no one can find even if they are looking for it. On the relationship between disease activity and glucocorticoid disease. https://t.co/aT8I0jwQOJ @rheum_covid @ARD_BMJ https://t.co/7ntGLPdypJ

Links:

The COVID-19 Global Rheumatology Alliance rheum_covid ( View Tweet)
Dr. Robert Rosenberg, a founding physician of Arthritis and Rheumatism Associates, is retiring after 44 years effective 5/31/22. ARA extends our deepest gratitude and sincerest thanks for his decades of service and exceptional patient care. We wish him well in his retirement. https://t.co/mYQODUk5VY
Arth and Rheum Assoc ARARheum ( View Tweet)
At a time when most American doctors have never seen measles, I think we should stop calling things morbilliform.

Adam Cifu adamcifu ( View Tweet)

Differential diagnosis of dysphagia - when due to autoimmune dz is called Autoimmune neurogenic dysphagia - causes include inflammatory myopathies,inclusion body myositis, myasthenia gravis, Guillain–Barre, MS, NMO, paraneoplastic neuropathies https://t.co/oA0cPVJ5pJ https://t.co/58MyQwmxhL

Links:

Dr. John Cush RheumNow ( View Tweet)
⭐️Ethics of placebo-controlled trials in PsA ➡️move toward active comparator designs. Need to use measures of deeper response (e.g., ACR 50, PASI100). ⭐️Assesing safety: LTE studies not adequate. Use of phase 4 studies or observational data but beware confounding by indication

Rheum Cat rheum_cat ( View Tweet)

SARS-CoV-2-infected alveoli (specifically N protein-coding plasmid alone) induces IL-6 production. Also, COVID-19 Sera also induced IL-6, moreso in those w/ severe disease. anti-N Ab promotes IL-6 production & may lead to cytokine storm https://t.co/jfPNwZM0g8 https://t.co/FwIs11i2qc

Links:

Dr. John Cush RheumNow ( View Tweet)
Tonight!: Join us for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A. 7pm ET | Join on Zoom or watch LIVE on RheumNow Twitter, LinkedIn and Facebook. https://t.co/Y6MtCItIxw https://t.co/ysRM3cWyYa

Links:

Dr. John Cush RheumNow ( View Tweet)
Data from Scleroderma Lung Study (CTX vs MMF in PSS) shows that early progression of ILD by CXR scoring (≥ 2% at 12 or 24 months) experienced significantly worse long-term survival than those with stable Xrays (P = .014). https://t.co/BVy0WEE6G8 https://t.co/e6NN7nxNDt

Links:

Dr. John Cush RheumNow ( View Tweet)
24 week, Phase II RCT of baricitinib in 314 active #SLE patients showed significant reductions in levels of dsDNA, IgG, Sm & ACL Abs; but had no effect on C3/C4, RNP, SSA, SSB. Changes in dsDNA did not correlate with SRI-4 responses though.https://t.co/cF6rHbtvf9 https://t.co/zXnUImaLHF

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved baricitinib (Olumiant) for the Treatment of Certain Hospitalized Patients with COVID-19 who require supplemental O2, mechanical ventilation, ECMO. Rec dose: 4-mg once daily for 14 days or until hospital discharge https://t.co/RiEp01tc0v https://t.co/f3RvUAzdRp

Links:

Dr. John Cush RheumNow ( View Tweet)
×